228 related articles for article (PubMed ID: 31770111)
1. The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.
Balbino B; Herviou P; Godon O; Stackowicz J; Goff OR; Iannascoli B; Sterlin D; Brûlé S; Millot GA; Harris FM; Voronina VA; Nadeau KC; Macdonald LE; Murphy AJ; Bruhns P; Reber LL
J Clin Invest; 2020 Mar; 130(3):1330-1335. PubMed ID: 31770111
[TBL] [Abstract][Full Text] [Related]
2. Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII.
Clay CD; Strait RT; Mahler A; Khodoun MV; Finkelman FD
J Allergy Clin Immunol; 2018 Apr; 141(4):1373-1381.e5. PubMed ID: 28624610
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis.
Baker DL; Nakamura GR; Lowman HB; Fischer SK
AAPS J; 2016 Jan; 18(1):115-23. PubMed ID: 26340860
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
5. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab.
Mirkina I; Schweighoffer T; Kricek F
Immunol Lett; 2007 Apr; 109(2):120-8. PubMed ID: 17368811
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
8. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.
Price KS; Hamilton RG
Allergy Asthma Proc; 2007; 28(3):313-9. PubMed ID: 17619560
[TBL] [Abstract][Full Text] [Related]
9. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
10. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
11. CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice.
Meyer T; Robles-Carrillo L; Davila M; Brodie M; Desai H; Rivera-Amaya M; Francis JL; Amirkhosravi A
Blood; 2015 Nov; 126(19):2230-8. PubMed ID: 26396093
[TBL] [Abstract][Full Text] [Related]
12. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab in allergic diseases, a recent review.
Vichyanond P
Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in children.
Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
[TBL] [Abstract][Full Text] [Related]
15. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
D'Amato G; Bucchioni E; Oldani V; Canonica W
Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
Félix Toledo R; Negro Alvarez JM; Miralles López JC
Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
[TBL] [Abstract][Full Text] [Related]
17. Vaccines targeting IgE in the treatment of asthma and allergy.
Peng Z
Hum Vaccin; 2009 May; 5(5):302-9. PubMed ID: 19221515
[TBL] [Abstract][Full Text] [Related]
18. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
19. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
Kuo BS; Li CH; Chen JB; Shiung YY; Chu CY; Lee CH; Liu YJ; Kuo JH; Hsu C; Su HW; Li YF; Lai A; Ho YF; Cheng YN; Huang HX; Lung MC; Wu MS; Yang FH; Lin CH; Tseng W; Yang J; Lin CY; Tsai PH; Chang HK; Wang YJ; Chen T; Lynn S; Liao MJ; Wang CY
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912861
[TBL] [Abstract][Full Text] [Related]
20. Advances in anti-IgE therapy.
Yalcin AD
Biomed Res Int; 2015; 2015():317465. PubMed ID: 26075226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
